Cargando…
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
BACKGROUND: A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study dose-escalation trial. Here, we report the interim results of the Phase IIb HH-2, where the immunogenicity and safety of a h...
Ejemplares similares
-
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2
por: Leal, Lorna, et al.
Publicado: (2023) -
Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates
por: Prenafeta, Antoni, et al.
Publicado: (2023) -
Role of Siglecs in viral infections: A double-edged sword interaction
por: Raïch-Regué, Dàlia, et al.
Publicado: (2023) -
The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
por: Borralleras, Cristina, et al.
Publicado: (2023) -
PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors
por: Shin, Yooju, et al.
Publicado: (2015)